Curr Pharm Design 18(1):9199 Nabavi SF, Braidy N, Gortzi O, Sobarzo-Snchez E, Daglia M, Skalicka-Woniak K, Nabavi SM (2015) Luteolin as an anti-inflammatory and neuroprotective agent: A brief review
These cases reveal important patterns about timing, severity, and resolution that can guide both patients and clinicians
Phasing out treatment towards a maintenance (too) low dosage-frequency
10.1073/pnas.0711986105 16
References Corona G, Giagulli VA, Maseroli E, et al
Its unique position as a naturally occurring, endogenous gene modulator distinguishes it from synthetic peptides in an important way: it works with the bodys existing regulatory systems rather than overriding them